Literature DB >> 1349640

Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems.

M Johnson1, I Elayan, G R Hanson, R L Foltz, J W Gibb, H K Lim.   

Abstract

The effects of 3,4-dihydroxymethamphetamine (DHM) and 2,4,5-trihydroxymethamphetamine (THM) on central serotonergic and dopaminergic systems were investigated to determine if these metabolites share the neurochemical properties of 3,4-methylenedioxymethamphetamine. THM (50-200 micrograms) or DHM (135 micrograms) was administered i.c.v. to rats; 5 days later, cortical, striatal and hippocampal tryptophan hydroxylase (TPH) activity were decreased by THM in a dose-dependent manner, whereas DHM was without effect in these brain structures. The concentration of serotonin in the brain structures contralateral to the side of THM injection was also decreased, but to a lesser degree. THM (100 and 200 micrograms) increased TPH activity to 155% of control in the dorsal raphe, whereas a dose of 50 micrograms increased TPH activity to 132% of control in the median raphe nucleus. THM also markedly reduced striatal tyrosine hydroxylase activity, but did not alter enzyme activity in the substantia nigra; DHM increased striatal tyrosine hydroxylase activity to 115% of control. These results suggest that THM, but not DHM, is toxic to both dopaminergic and serotonergic nerve terminals. Although THM could not be established as the neurotoxic metabolite explaining 3,4-methylenedioxymethamphetamine (MDMA) toxicity, its properties may prove useful in elucidating amphetamine toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349640

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  The use of toxicokinetics for the safety assessment of drugs acting in the brain.

Authors:  D B Campbell
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

2.  A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice.

Authors:  Isabel Escobedo; Esther O'Shea; Laura Orio; Veronica Sanchez; Mireia Segura; Rafael de la Torre; Magi Farre; Alfred Richard Green; Maria Isabel Colado
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

3.  Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.

Authors:  M I Colado; E O'Shea; R Granados; B Esteban; A B Martín; A R Green
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  Synthesis and neurotoxicity profile of 2,4,5-trihydroxymethamphetamine and its 6-(N-acetylcystein-S-yl) conjugate.

Authors:  Anne Neudörffer; Melanie Mueller; Claire-Marie Martinez; Annis Mechan; Una McCann; George A Ricaurte; Martine Largeron
Journal:  Chem Res Toxicol       Date:  2011-05-18       Impact factor: 3.739

Review 5.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 6.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

7.  Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Anne Felim; Anne Neudörffer; Frank T Peters; Hans H Maurer; Una D McCann; Martine Largeron; George A Ricaurte
Journal:  Drug Metab Dispos       Date:  2009-07-23       Impact factor: 3.922

8.  The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

Authors:  M I Colado; J L Williams; A R Green
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 9.  Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Authors:  A R Green; A J Cross; G M Goodwin
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

10.  New Insights on Different Response of MDMA-Elicited Serotonin Syndrome to Systemic and Intracranial Administrations in the Rat Brain.

Authors:  Ibrahim M Shokry; John J Callanan; John Sousa; Rui Tao
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.